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Abstract
The current investigation describes the pharmacokinetic–pharmacodynamic correlation of the hypothermic and the corticosterone effect
of flesinoxan in the rat simultaneously. A specific objective was to determine the influence of handling the animal. The pharmacokinetic–
pharmacodynamic correlation was determined following intravenous administration of 3 and 10 mg/kg flesinoxan in 5 or 15 min. Serial
blood samples were obtained for determination of the time course of the flesinoxan and corticosterone concentrations by high performance
liquid chromatography. Body temperature was monitored using a telemetric probe. The pharmacokinetics of flesinoxan were described using
a three-compartment model. Both the hypothermic and the corticosterone response were successfully described using a physiological indirect
response model. It is shown that customizing the animal prior to the experiment has no influence on the pharmacokinetic–pharmacodynamic
parameter estimates. Furthermore, the similarity in potency between the hypothermic and corticosterone effects suggests that both are
mediated via tissues with a similar receptor–effector coupling efficiency. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Flesinoxan is a new 5-HT1A receptor agonist with
improved oral absorption characteristics compared to classi-
cal 5-HT1A receptor agonists. In in vitro test systems, the
drug behaves as a full agonist with an intrinsic activity
similar to R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (R-
8-OH-DPAT). Flesinoxan exhibits a high selectivity for the
5-HT1A receptor relative to the 5-HT7 subtype. Furthermore,
unlike buspirone for example, in vivo flesinoxan is not
converted into an active metabolite, which may interfere
with the pharmacological activity of the parent compound
(Hadrava et al., 1995; Millan et al., 1993; Seletti et al., 1995).
Recently, we have proposed an integrated pharmacoki-
netic–pharmacodynamic model for the effect of 5-HT1A
receptor agonists using the effect on body temperature as a
pharmacodynamic endpoint (Fig. 1; Zuideveld et al., 2001).
Briefly, this model is based on the principle of a set-point
control in an indirect physiological response model (Day-
neka et al., 1993) and is able to characterise quantitatively
the effect of 5-HT1A receptor agonists in vivo. In this model,
the set-point for maintenance of body temperature is atte-
nuated by 5-HT1A receptor agonist via a sigmoidal trans-
ducer function. This model has been applied successfully to
explain the hypothermic response observed in rats after
administration of the 5-HT1A receptor agonists R- and S-
8-OH-DPAT in terms of potency and intrinsic activity
(Zuideveld et al., 2001). Furthermore, the model has also
recently been applied successfully to quantify the effect of
the competitive 5-HT1A receptor antagonist N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-cyclo-
hexanecarboxamide (WAY-100,635) in vivo (Zuideveld et
al., 2002).
The present investigation focuses on the pharmacoki-
netic–pharmacodynamic correlation of flesinoxan in the
temperature model. The primary objective was to deter-
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pharmacodynamic correlation. A secondary objective was
to compare the pharmacodynamics for the effect on body
temperature with the effect on corticosterone concentration.
In several studies, a wide range of different pharmaco-
logical responses for flesinoxan have been examined
(Hadrava et al., 1995; Ahlenius et al., 1991; Groenink et
al., 1997). However, very few studies have focused on two
effects (i.e. the hypothermic and the corticosterone response)
simultaneously (De Koning and De Vries, 1995). Inherent to
investigating corticosterone levels in rats, is the need for
‘handling’ in order to maintain a stable corticosterone base-
line. It has been shown that corticosterone levels in non-
handled rats will increase regardless of any drug being
administered (Bassett et al., 1973). Handling the rat a
number of times results in a number of corticosterone surges
prior to the experiment. It is well established that exposure to
corticosterone may influence the level of 5-HT1A receptor
expression (Chaouloff, 1993, 1995; Le Corre et al., 1997;
Sibug et al., 2000), and thereby the 5-HT1A mediated
pharmacological response. Therefore, the present study
was specifically aimed at the characterisation of possible
pharmacodynamic adaptations due to handling. Further-
more, as the 5-HT1A-mediated increase in corticosterone as
well as the hypothermic response can quantified in terms of
intrinsic activity and potency, both effects can be compared.
2. Materials and methods
Experiments were performed on male Wistar rats
(Broekman, Someren, The Netherlands) weighing 283F4g
(meanFS.E.M., n=42) and were approved by the Leiden
University Ethics Committee. The animals were housed in
standard plastic cages (six per cage before surgery and
individually after surgery). They were kept in a room with a
normal 12 h light/dark cycle (lights on at 7:00 a.m. and
lights off at 7:00 p.m.) and a temperature of 21 jC. During
the light period, a radio was on for background noise.
Acidified water and food (laboratory chow, Hope Farms,
Woerden, the Netherlands) was provided ad libitum before
the experiment.
2.1. Surgical procedure
Eight days prior to the experiment, the rats were operated
upon. The animals were anaesthetised with an intramuscular
injection of 0.1 ml/kg Domitor (1 mg/ml medetomidine
hydrochloride, Pfizer, Capelle a/d IJsel, The Netherlands)
and 1 ml/kg Ketalar (50 mg/ml Ketamine base, Pfizer,
Hoofddorp, The Netherlands). Indwelling pyrogen-free can-
nulae for drug administration were implanted into the right
jugular vein (polythene, 14 cm, 0.52 mm i.d., 0.96 mm o.d.)
for regular infusions of flesinoxan. For blood sampling, the
left femoral artery (polythene, 4 cm, 0.28 mm i.d., 0.61 mm
o.d.+20 cm, 0.58 mm i.d., 0.96 mm o.d.) was cannulated.
Cannulae were tunnelled subcutaneously to the back of the
neck and exteriorised. To prevent coagulation of blood, the
cannulae were filled with a 25% (w/v) solution of poly-
vinylpyrolidone (Brocacef, Maarssen, The Netherlands) in a
0.9% (w/v) sodium chloride solution (NPBI, Emmer-Com-
pascuum, The Netherlands, pyrogen-free) that contained 50
I.U./ml heparin (Leiden University Medical Center, Leiden,
The Netherlands). Just before the experiment, the polyvi-
nylpyrolidone solution was removed and the cannulae were
flushed with saline containing 20 I.U./ml heparin. The skin
in the neck was stitched with normal suture and the skin in
the groin was closed with wound clips. Furthermore, a
telemetric transmitter (Physiotel implant TA10TA-F40 sys-
tem, Data Sciences International (DSI), St. Paul, MN, USA)
(weighing F7 g), which had been made pyrogen-free with
CIDEX (22 g/l glutaraldhyde, Johnson & Johnson Medical,
Gargrave, Skipton, UK) for at least 2 h, was implanted into
the abdominal cavity for the measurement of core body
temperature. After surgery, an injection of the antibiotic
ampicilline (ampicilline trihydrate 200 mg/ml, A.U.V.,
Cuijk, The Netherlands) was administered to aid recovery.
2.2. Experimental protocol
2.2.1. Dosage regimen
Eight days after surgery the experiments were performed.
Rats were divided into two groups, 12 rats would undergo a
handling procedure and 30 would not. The handling proce-
dure involved accustoming the rats to the investigators,
experimental stetting and experimental procedures by ‘prac-
ticing’ the experiment six times (i.e. days) prior to the actual
experiment. Of this group, six rats received 3 mg/kg
flesinoxan in 5 min and six received a vehicle treatment.
Fig. 1. Full model for describing 5-HT1A receptor mediated hypothermia.
The model is based on the concepts of the indirect physiological response
model, and takes into account rate constants associated with the warming of
the body (kin) and cooling of the body (kout). The indirect physiological
response model is combined with the thermostat-like regulation of body
temperature, in which body temperature (T) is compared with a fixed
reference or set-point temperature (TSP) at rate a, generating a set-point
signal X. The extent to which the set-point value decreases is a function of
drug concentration f(C), which decreases X by the amplification factor c.
(Reproduced with permission from Zuideveld et al. (2001)).
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Flesinoxan was administered 3 mg/kg in 5 min (n=6), 10
mg/kg in 5 or 15 min (n=6 per group) infusion. Vehicle
infusions consisted of administration of equivalent amounts
of saline. For the infusions, an external cannula with a
specific volume was filled with a solution of the drug in an
amount of saline, which was calculated according to the
weight of the rat and connected to the infusion pump (BAS
beehive, Bioanalytical Systems USA). All the experiments
started at 9:00 a.m.
2.2.2. Blood sampling
At predefined times, two serial blood samples of 50 Al
each were taken to determine both the concentration of the
drug and the concentration of corticosterone. Approximately
15 samples were taken according to a fixed time schedule.
The exact amount was measured with a capillary and
transferred into either a glass centrifuge tube containing
400 Al of Millipore water for hemolysis (pharmacokinetic
samples) or an Eppendorf-vial containing 50 Alo fa1 %
EDTA solution in saline (pH 7.4) (corticosterone samples).
During the experiment, the samples were kept on ice. After
the experiment, pharmacokinetic samples were stored at
 20 jC pending analysis. The corticosterone samples were
centrifuged and 70 Al of ‘plasma’ was transferred to a clean
tube and stored at  20 jC pending analysis.
2.3. Data acquisition
2.3.1. Temperature measurements
To measure the body temperature of the rat, a telemetric
system (Physiotel Telemetry system, DSI) was used. A
telemetric transmitter (Physiotel implant TA10TA-F40,
DSI) was implanted in the abdominal cavity of the rat.
The transmitter measured the body temperature every 30 s
for a 2-s period and signalled it to a receiver (Physiotel
receiver, model RPC-1, DSI). The receiver was connected to
the computer through a BCM 100 consolidation matrix
(DSI). The computer processed the data and visualised the
temperature profiles (Dataquest LabProk software, DSI,
running under OS/2 Warp, IBM) as it did for room temper-
ature (C10T temperature, DSI).
2.3.2. HPLC analysis of flesinoxan
The blood concentrations of flesinoxan were assayed by
an enantioselective high performance liquid chromatogra-
phy (HPLC) method, slightly modified from one described
previously (Van der Sandt et al., 2001a). Briefly, detection
with the HPLC system was obtained using an electrochem-
ical detector (DECADE, Antec Leyden, Zoeterwoude, The
Netherlands) operating in DC mode at 0.63 V, at a temper-
ature of 30 jC. Chromatography was performed on a
Chiralcel OD-R (Diacel Chemical Industries, Tokyo, Japan).
The mobile phase was a mixture of 50 mM phosphate buffer
(pH 5.5) acetonitrile (75:25, v/v) and contained a total
concentration of 5 mM KCl and 20 mg/l of EDTA (flow,
1 ml/min). The chromatograms were analysed using Mil-
lennium-Chromatography Manager (Waters, Milford, MA,
USA). The analytes were extracted from blood using two
liquid–liquid extraction steps. Briefly, to 50 Al of blood
hemolyzed in 400 Al of water, 50 Al of the internal standard
DU-28848 was added. After mixing, 2 ml of acetonitrile
was added, vortexed and centrifuged. To the supernatant,
0.5 ml 8% acetic acid solution, together with a 2 ml
methylisobutylketon/ether (50:50, v/v) mixture was added.
After vortexing for 2 min, the organic layer was removed
and 1 ml of a 1 M NaOH solution together with 3 ml of
dichloromethane was added. After mixing, the water phase
was removed and the organic phase was evaporated. The
remaining residue was redissolved in 100 Al of a 20%
acetonitrile solution. Calibration curves in the concentration
range of 0.1–5000 ng/ml were constructed and analysed
with each run by weighted linear regression ([weight fac-
tor=1/(peak area ratio]
2). Recovery, intra- and inter-assay
variations were determined using spiked blood of 50 and
1000 ng/ml. For flesinoxan, the recovery was (n=3, mean)
76% over the whole concentration range (external standard
method and corrected for loss of volume). Intra-assay
variation (n=4) was 5.9% and 4.2% (accuracy: 1.8% and
4.5%) for 500 and 1500 ng/ml. Inter-assay variation (n=10)
was 9.1% and 6.7% (accuracy: 4.0% and  0.03%) for 500
and 1500 ng/ml. Detection limit (signal to noise ratio of 3)
using 50 Al of blood was 0.06 ng/ml.
2.3.3. HPLC analysis of corticosterone
The blood concentrations of corticosterone were assayed
by a HPLC method which was slightly modified from a
method by Wong et al. (1994). Briefly, detection with the
HPLC system was obtained using an UV detector (Spectro-
flow 757, Kratos Analytical Instruments) operating at 254
nm. Chromatography was performed using a reversed phase
C-18 column (microsphere C-18, 3 Am, 10 cm 4.6 mm
i.d., Chrompack). The mobile phase consisted of a mixture
of acetonitrile/water/acetic acid (35:65:0.05, v/v/v) with a
pH of 3. The pump (Spectroflow 400, Kratos analytical
Instruments) was set at a flow rate of 1 ml/min and the
samples were injected using an autosampler (WISP 712,
Waters). Chromatograms were analysed using an integrator
(Shimadzu CR3A, Shimadzu Kyoto, Japan). The analytes
were extracted from the plasma/saline mixture using a
liquid/liquid extraction. To 50 Al of the plasma mixture,
50 Al of the internal standard dexamethasone, 5 ml dichloro-
methane and 0.5 ml 3 M NaOH were added. After vortexing
and centrifuging, the water-phase was removed and the
organic phase was evaporated at 30 jC. The dry residue
was redissolved in 100 Al 25% ethanol, of which 50 Al was
injected into the HPLC system. The plasma used for the
calibration curve was produced from blood of untreated rats.
All endogenous corticosterone was removed by adding an
equal volume of 0.04 g/ml active coal to a volume of
plasma. After vortexing for 90 min, the suspension was
centrifuged for 60 min at 5000 rpm and the plasma was
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Schuell, Dassel, Germany). Calibration curves in the con-
centration range of 5–1000 ng/ml were constructed and
analysed with each run by weighted linear regression
([weight factor=1/(peak area ratio]
2). Recovery, intra- and
inter-assay variations were determined using spiked plasma
of 50 and 1000 ng/ml. Recovery was (n=3, meanFS.E.M.)
90% over the whole concentration range. Intra-assay varia-
tion (n=4) was 8.9% and 2.7% (accuracy: 6.7% and  1.9%)
for 50 and 1000 ng/ml. Inter-assay variation (n=10) was
10.9% and 6.9% (accuracy: 4.6% and  1.8%) for 50 and
1000 ng/ml. Detection limit (signal to noise ratio of 3) using
50 Al of plasma was 5.6 ng/ml.
2.3.4. Chemicals
Solvay Pharmaceuticals (Weesp, The Netherlands)
generously donated flesinoxan and its 3-hydroxymethyl
analogue, DU-28848 (N-[2-[4-[2,3-dihydro-3-(hydroxy-
methyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluro-
benzamide hydrochloride). Corticosterone and dexametha-
sone were obtained from Sigma (The Netherlands).
Dichloromethane was purchased from Riedel-De Hae ¨n
(Seelze, Germany). All other chemicals used were of ana-
lytical grade (Baker, Deventer, The Netherlands).
2.4. Data analysis
A population approach was utilised to quantify both the
pharmacokinetics and pharmacodynamics of flesinoxan.
Using this approach, the population is taken as the unit of
analysis while taking into account both intra-individual
variability in the model parameters as well as inter-individ-
ual residual error (Schoemaker et al., 1998). Modelling was
performed using the non-linear mixed effects modelling
software NONMEM developed by Boeckman et al. (1992)
(Version V 1.1, NONMEM project Group, University of
California, San Francisco, USA). Individual predictions
were obtained in a Bayesian post hoc step.
2.4.1. Pharmacokinetic analysis
The concentration–time profiles of the flesinoxan were
best described using a three-compartment pharmacokinetic
model,
V1
dC
dt
¼ in   Cl   C   Cl2   C þ Cl2   C2   Cl3   C þ Cl3
  C3,
V2
dC2
dt
¼ Cl2   C   Cl2   C2,
V3
dC3
dt
¼ Cl3   C   Cl3   C3, ð1Þ
where C represents the concentration in the central compart-
ment and C2 and C3 the concentration in the distribution
compartments. V1, V2 and V3 are the compartments’ vol-
umes of distribution. Cl represents the Clearance and Cl2
and Cl3 the inter-compartmental clearance. For an infusion,
in is defined by Eq. (2).
in ¼
Doseinf
Tinf
when t V Tinf,
in ¼ 0 when t > Tinf, ð2Þ
where Tinf is the duration of the infusion and Doseinf is the
total amount of drug infused. The model implemented in
NONMEM’s ADVAN11 TRANS4 was used. For all mod-
els, inter-individual variability on the parameters was mod-
elled by an exponential equation,
Pi ¼ h   expðgiÞ, ð3Þ
where h is the population value for parameter P, Pi is the
individual value and gi is the random deviation of Pi from P.
The values of gi are assumed to be independently normally
distributed with mean zero and variance x
2. Residual error
was characterised by a proportional error model:
Cmij ¼ Cpijð1 þ eijÞ, ð4Þ
where Cpij is the jth plasma concentration for the ith
individual predicted by the model, Cmij is the measured
concentration, and e accounts for the residual deviance of
the model predicted value from the observed concentration.
The values for e are assumed to be independently normally
distributed with mean zero and variance r
2. The values for
the population h, x
2, r
2, are estimated using the first-order
method in NONMEM.
2.4.2. Pharmacodynamic analysis
The time course of the hypothermic response and the
effect on corticosterone release were analysed on the basis
of physiological indirect response models. In these models,
the drug–receptor interaction generates a stimulus, which in
turn drives physiological processes. This stimulus character-
ises the drug–receptor interaction in terms of the drugs’
intrinsic activity and potency, and can be described by the
sigmoidal model f(C),
f ðCÞ¼S ¼
Smax   Cn
SCn
50 þ Cn , ð5Þ
where S is the stimulus, Smax is the maximum stimulus the
drug can produce, C is the drug concentration, SC50 is the
concentration required to produce 50% of the maximum
stimulus and n is the slope factor, which determines the
steepness of the curve.
2.4.2.1. Hypothermic response. Recently, we have devel-
oped a physiological model to describe the time course of
the hypothermic response in vivo following the administra-
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2001). The model features a set-point control that can be
attenuated by the drug receptor interaction (f(C)) in combi-
nation with an indirect physiological response model (Day-
neka et al., 1993). This model considers a zeroth order rate
constant associated with the warming of the body (kin) and a
first-order rate constant associated with the cooling of the
body (kout). The thermostat-like regulation is implemented
as a continuous process in which body temperature (T)i s
compared with a fixed reference or set-point temperature
(TSP). 5-HT1A receptor agonists elicit hypothermia by
decreasing the set-point value in a non-linear manner as a
function of their concentration f(C), according to:
dT
dt ¼ kin   kout   T   X  c,
dX
dt ¼ aðTSP  ½ 1   f ðCÞ    TÞ,
8
<
:
ð6Þ
in which X denotes the thermostat signal, which is driven by
the difference between the body temperature T and the set-
point temperature TSP on a time-scale governed by a. Hence,
when the set-point value is lowered, the body temperature is
perceived as too high and X is lowered. The decreasing
signal relates to the drop in body temperature via an effector
function X
 c,i nw h i c hc determines the amplification.
Raising this function to the loss term kout T therefore
facilitates the loss of heat. With four system parameters to
be estimated, the degree of parameterization in Eq. (6) is
high and this may lead to parameter identifiability problems.
It can be shown that one parameter can be eliminated in a
procedure involving redefinition of variables (Zuideveld et
al., 2001). The procedure results in the definition of the
parameters A and B where,
A ¼
a   T0
X0
¼ a
kin
kout
   1
c
T
1  1
c ðÞ
0 and B ¼
kin
T0
, ð7Þ
where T0 and X0 are the values for T and X when no drug is
present. Hence, four physiological parameters are reduced to
three, and parameter unidentifiability is abolished.
As a result of the introduction of dimensionless quanti-
ties, the dependent variable T is rescaled to y. The procedure
for calculating the redefined y-values on the basis of the
observed temperatures is represented in Eq. (8),
y ¼
T   Tmin
TSP   Tmin
: ð8Þ
In Eq. (8), T is the temperature at time t, TSP is the average
temperature from the hour prior to drug administration and
T
_
min is the average minimal temperature of rats receiving a
dose of the full agonists R-8-OH-DPAT (33.1 jC, Zuideveld
et al., 2001). This temperature is used as the maximal
response as defined by Smax equals 1 for a full agonist,
such as R-8-OH-DPAT.
2.4.2.2. Corticosterone response. The plasma corticoster-
one concentration–time profiles were described by an
indirect physiological response model (Dayneka et al.,
1993);
d½Corticosterone 
dt
¼ kin   f ðCÞ kout  ½ Corticosterone ,
ð9Þ
where Corticosterone represents the corticosterone concen-
tration, f(C)=S (Eq. (5)), kin is a zeroth order rate constant
associated with the production of corticosterone and kout a
first-order rate constant associated with the elimination of
corticosterone. The baseline or no-drug level of cortico-
sterone, [Corticosterone]0, can be defined in terms of kin and
kout;
½Corticosterone 0 ¼
kin
kout
 ð 10Þ
2.4.2.3. Modelling. Both pharmacodynamic models were
implemented in NONMEM using ADVAN6. For the mod-
elling of the effect on body temperature parameterisation is
different from Eq. (7), where B is purely phenomenological.
However, as the individual TSP values are known, the
parameter B can be calculated from kin. Therefore, the
estimated physiological parameters were kin, A and c. Initial
estimates of the model parameters were obtained by simu-
lation. The observed time dependent variable temperature
measurements were redefined as described in Eq. (8). For
the effect on corticosterone on basis of Eq. (9), kin was
estimated using Eq. (10) since baseline corticosterone con-
centration was measured. For both models, inter-individual
variability on the parameters was modelled to an exponen-
tial equation, such as described in Eq. (3). Residual error
was characterised by a proportional error model:
ymij ¼ ypij  ð 1 þ eijÞ, ð11Þ
where ypij is the jth prediction for the ith individual pre-
dicted by the model, ymij is the measurement, and e ac-
counts for the residual deviance of the model predicted
value from the observed value. The values for the popu-
lation h, x
2, r
2, in the set-point model are estimated using
the centering first-order conditional estimation method
with the first-order model in NONMEM. A conditional
estimation method was used due to the high degree of non-
linearity of the model and the high density of the data. The
centering option gives the average estimate of each ele-
ment of g together with a P-value which can be used to
assess whether this value is sufficiently close to zero. The
occurrence of an average g that is significantly different
from zero indicates an un-centered or a biased fit. In order
to reduce computing time as required with just the condi-
tional estimation method, this method was chosen, and not
because the average estimates of each element of g were
expected to be different from zero (Boeckman et al., 1992;
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ing time only 1/16th of the temperature data was used for
modelling, thereby reducing the temperature measurements
from over 900 measurements per individual to approxi-
mately 60. The implication of this reduction is that there is
a data point every 8 min, as opposed to every 0.5 min.
This reduction did not void the integrity of the data
profiles. The values for the population h, x
2 and r
2, for
the corticosterone response are estimated using the first-
order method in NONMEM.
Fig. 2. (A) Pharmacokinetic profiles of flesinoxan in non-handled rats after
administration of 3 mg/kg in 5 min (n=6), 10 mg/kg in 5 min (n=6) and 10
mg/kg in 15 min (n=6). Both the individually measured profiles (dashed
lines with markers) and the individual prediction (thick line) are re-
presented. The last tick on the x-axis represents 35 h, the intervals of the
ticks after the axis-break is 5 h. (B) Accompanying average temperature–
time profiles (FS.E.M.) for vehicle treatment (1, n=12), the 3 mg/kg in 5
min, (2), 10 mg/kg in 5 min (3) and 15 min (4) treatments. All infusions
started at t=0.
Fig. 3. (A) Pharmacokinetic profiles of flesinoxan after administration of 3
mg/kg in 5 min in handled and non-handled rats (both n=6). Individually
measured concentration profiles are represented by dashed lines with
markers, whereas the individual predictions are represented by a thick line.
The last tick on the x-axis represents 35 h, the intervals of the ticks after the
axis-break is 5 h. (B) Accompanying average temperature–time profiles
(FS.E.M.) for vehicle treatments (1 and 2) and flesinoxan treatments (3 and
4) for handled (1 and 3) and the non-handled (2 and 4) rats. All infusions
started at t=0.
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Goodness-of-fit was analysed using the objective func-
tion, and various diagnostic methods as present in Xpose
version 3.04 (S-plus based model building aid (Jonsson and
Karlsson, 1997)). Model selection was based on the Akaike
Information Criterion (Akaike, 1974) and assessment of
parameter estimates and correlations.
3. Results
Fig. 2 shows the average plasma concentration and
hypothermic effect versus time profiles of flesinoxan in
non-handled rats following the administration of 3 mg/kg in
5 min (n=6), 10 mg/kg in 5 min (n=6) and 10 mg/kg in 15
min (n=6), respectively. The average baseline temperature
(FS.E.M., n=12) was 37.95F0.004 jC. Following admin-
istration of 3 and 10 mg/kg a maximal decrease in body
temperature of 3.0F0.44 and 3.8F0.20 jC was observed
after approximately 24 and 54 min, respectively. After
reaching the temperature minimum, upon administration
of 3 mg/kg, a sharp increase followed by a ‘plateau phase’
is observed before the body temperature returns to baseline
after approximately 6 h (Fig. 2B). The plateau phase is also
observed, but to a lesser extent, after administration of 10
mg/kg, and the effect after reaching the minimum body
temperature returns to baseline more gradually after 9 h
(Fig. 2B).
Fig. 3 shows the concentration and hypothermic effect
versus time profiles following administration of 3 mg/kg in
handled and non-handled rats. The average baseline temper-
ature (FS.E.M., n=6) was 38.24F0.007 jC for the handled
rats, which was statistically significantly different from the
non-handled ones (P<0.0001). Following administration of
3 mg/kg of flesinoxan (n=6) a maximal decrease in body
temperature of 3.0F0.27 jC was observed after approxi-
mately 28 min. The maximal decrease following a 3 mg/kg
administration of flesinoxan between the handled and the
Fig. 4. Average corticosterone–time profiles (FS.E.M.) for (A), non-
handled rats which had received vehicle treatments (open circles, n=12), 3
mg/kg in 5 min (closed circles, n=6), 10 mg/kg in 15 min (closed squares,
n=6) or 15 min (closed triangles, n=6) of flesinoxan. (B) Handled rats
which had received vehicle treatment (open circles, n=6) and 3 mg/kg in 5
min (closed circles, n=6). All flesinoxan infusions started at t=0.
Table 1
Population pharmacokinetic parameters and inter- and intra-individual
variabilities of flesinoxan
Drug Parameter Value CV inter-
individual
(%)
95% C.I. Unit
Flesinoxan
(non-handled
and handled)
Cl 2.96 51 2.48–3.43 ml/min
Cl2 0.827 59 0.393–1.261 ml/min
Cl3 48.1 39 39.8–56.4 ml/min
V1 10.2 70 5.06–15.3 ml
V2 226 61 151–301 ml
V3 347 30 305–389 ml
CV intra-individual: 23%
CV inter-individual is the inter-individual coefficient variation, CV intra-
individual is the intra-individual coefficient of variation and 95% C.I. is the
95% confidence interval over the precision of the estimated parameter.
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(P>0.99) and the time versus effect profiles show a similar
plateau phase (Fig. 3B).
The average time–effect profiles for the corticosterone
concentrations after administration of vehicle and flesinoxan
in both non-handled and handled rats are depicted in Fig. 4.
For non-handled rats, the average starting (1 h prior to the
infusion) concentration of corticosterone in blood (FS.E.M.)
was 170F55 ng/ml (n=12). Concentration started to rise
immediately after the first sample was taken (t= 60),
reaching a maximal concentration of 340F57, 430F130
and 460F17 ng/ml approximately 42, 10 and 45 min after
the start of the vehicle, 3 and 10 mg/kg infusions, respec-
tively. The increase in corticosterone lasted slightly longer
for the 10 mg/kg administration. The average baseline
concentration (entire experiment) for the handled rats was
170F12 ng/ml (n=6), identical to that observed in non-
handled rats. Following administration of 3 mg/kg (n=6) in
handled rats, a maximal concentration after the start of the
infusion of 320F45 ng/ml was observed after approxi-
mately 60 min, which is statistically significantly different
from baseline (P<0.01).
3.1. Pharmacokinetic analysis
During the experiments, blood samples were taken to
construct individual concentration–time profiles for flesi-
noxan. Individual-based concentration profiles were pre-
dicted by fitting the data to a population pharmacokinetic
model. On the basis of time–concentration curves, good-
ness-of-fit-plots and the minimum value of the objective
function, a three-compartment model was selected for
flesinoxan (Eq. (1)). The individually measured concentra-
tion profiles and the individually predicted curves are
represented in Figs. 2A and 3A. All parameters were
Table 2
Population pharmacodynamic parameters and inter- and intra-individual
variability’s of the hypothermic effect of flesinoxan using the set-point
model
Type/Drug Parameter Value CV inter-
individual
(%)
95% C.I. Unit
Physiological kin 2.23 49 1.91–2.55 jC/min
A 0.0167 76 0.0003–0.0331 min
 1
c 6.42 87  1.02–13.7 n.a.
Flesinoxan SC50 714 33 692–736 ng/ml
n 1.84 63 0.689–0.721 n.a.
Smax 0.705 43 1.81–1.71 n.a.
CV intra-individual: 11%
CV inter is the coefficient of variation and CV intra is the coefficient of the
random error. All the handled and non-handled rats were fitted together.
Table 3
Mean, median, lowest (min) and highest (max) values of the individually
estimated post hoc pharmacodynamic parameter estimates for all the non-
handled and handled rats
Non-handled Handled
Median Mean min–max Median Mean min–max
kin (jC/min) 2.19 2.46 1.23–6.693 2.27 2.18 1.59–2.83
A (min
 1) 0.017 0.016 0.009–0.022 0.017 0.019 0.016–0.026
c 6.94 6.78 3.93–9.30 7.05 7.69 6.84–10.7
SC50
(ng/ml)
526 656 237–1980 555 538 449–608
Smax 0.735 0.730 0.350–0.999 0.637 0.604 0.368–0.797
n 1.91 2.55 0.489–7.45 1.93 1.54 0.638–2.30
Table 4
Population pharmacodynamic parameters and inter- and intra-individual
variabilities of the corticosterone effect of flesinoxan on handled rats using
the indirect physiological response model
Type/Drug Parameter Value CV inter-
individual
(%)
95% C.I. Unit
Physiological kout 0.151 <1 0.0298–
0.2752
min
 1
kin 30.2 n.a. n.a. (ng/ml)/min
Flesinoxan SC50 462 <1 184–740 ng/ml
n 2.34 342 1.51–3.17 n.a.
Smax 1.58 126 1.21–1.95 n.a.
CV intra-individual: 42%
CV inter-individual is the coefficient of variation and CV intra-individual is
the coefficient of the random error. kin is derived from kout and the baseline
value.
Fig. 5. Selected representative fits of different treatments of flesinoxan both
handled and non-handled. Open circles represent measured body temper-
ature, solid line represents individual prediction and the dashed line the
population prediction. Infusions all started at t=60.
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being incorporated in exponential error models, which are
represented in Table 1. The pharmacokinetic parameters
were independent of administered dose and the duration of
the infusion. Furthermore, there were no differences in
pharmacokinetics between the handled and non-handled
rats. Table 1 further displays the inter-individual variation,
and the intra-individual variation, which were both found to
be reasonable. The precision of the parameters predictions,
as represented by their 95% confidence intervals, is good.
3.2. Pharmacodynamic analysis
The hypothermic effect–time profiles for both the
handled and the non-handled rats receiving flesinoxan were
described simultaneously by fitting the set-point model (Eq.
(8)) to the data. Potency and relative intrinsic activity of
flesinoxan in the hypothermic response were estimated at
714 ng/ml and 0.7, respectively. Parameters were estimated
using the centering first-order conditional estimation
method with a first-order model. The average values for
all g’s were not significantly different from zero. Population
parameter estimates are depicted in Table 2. Individual post
hoc predictions of the parameters were not found to be
biased with respect to the different doses and infusions.
Furthermore, no significant differences were found in the
individual post hoc estimates between the non-handled and
the handled rats as depicted in Table 3. The quality of the
fitting of the model to the data is further illustrated in Fig. 5,
showing the individual observations, predictions and pop-
ulation predictions for a number of representative rats.
The increase in corticosterone following administration
of flesinoxan for the handled rats is described by fitting the
indirect physiological response model (Eq. (9)) to the data.
Potency and intrinsic activity of flesinoxan in the cortico-
sterone response were estimated at 462 ng/ml and 1.58,
respectively. Parameters were estimated using the first-order
method. Population parameter estimates are depicted in
Table 4. Individual post hoc predictions of the parameters
were not found to be biased with respect to the different
administrations or treatment groups. The inter-individual
variation on the slope factor (n) and maximal stimulus
(Smax) is relatively large. Fig. 6 depicts the individual
observations, predictions and population predictions for a
number of typical rats.
4. Discussion
The objectives of the present investigation were: (a) to
determine the pharmacokinetic–pharmacodynamic correla-
tion of flesinoxan using the effect on body temperature as a
pharmacodynamic endpoint, (b) to study the influence of
‘handling’ on the pharmacokinetic–pharmacodynamic cor-
relation of flesinoxan, and (c) to compare the pharmacoki-
netic–pharmacodynamic relationship for the effect on body
temperature to the effect on blood corticosterone concen-
trations.
Both 5-HT1A receptor-mediated hypothermia and an
increase in corticosterone are well established and robust
markers for 5-HT1A receptor mediated activity (Millan et al.,
1993; Cryan et al., 1999; Matheson et al., 1996; Kelder and
Ross, 1992). However, despite the fact that numerous
studies report these responses for flesinoxan (Hadrava et
al., 1995; Seletti et al., 1995; Groenink et al., 1995, 1997)
few have studied both responses simultaneously (De Koning
and De Vries, 1995). Furthermore, there are no reports of
investigations where an integrated pharmacokinetic–phar-
macodynamic approach has been applied to obtain param-
eter estimates characterising the in vivo potency and
intrinsic activity on the basis of concentrations rather than
doses. One of the complicating factors when studying
corticosterone levels is the need for handling of the animals,
since corticosterone levels in non-handled rats will increase
regardless of the drug being administered (Bassett et al.,
1973, and see Fig. 4). It is well known that by handling or
accustoming the rats to the investigators and experimental
setting, i.e. by rehearsing the experiment a number of times
on the days prior to the experiment, corticosterone levels
will remain stable during the actual experiment (Bassett et
al., 1973 and see Fig. 4). It is our interpretation that hand-
ling actually involves stressing the rat a number of times,
until the procedure becomes a predictable experience for the
rat and hence less stressful. However, stressing the rat a
number of times results in a number of corticosterone surges
prior to the experiment. As it is well established that
changes in corticosterone exposure may influence the level
of 5-HT1A receptor expression and thereby potentially the
intensity of 5-HT1A receptor mediated responses (Chaoul-
off, 1993, 1995; Wissink et al., 2000; Le Corre et al., 1997),
the present study also focused on the question of whether
Fig. 6. Selected representative fits of the effect of flesinoxan on
corticosterone for handled rats. Both the individually measured profiles
(dashed lines with markers) and the population prediction (thick line) are
represented. Infusions all started at t=60.
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response between the handled and non-handled rats.
Upon administration of flesinoxan, a terminal elimination
half-life of 136 min is observed. Relative to other 5-HT1A
ligands such as R-8-OH-DPAT (86 min (Zuideveld et al.,
2001)), buspirone (25 min (Zuideveld et al., unpublished
observations)) and WAY-100,635 (33 min (Zuideveld et al.,
2002)), this is quite long. This explains the relatively long
duration of the hypothermic response after administration of
the highest dose. Interestingly, no differences in pharmaco-
kinetic parameter estimates were found between the differ-
ent doses and infusions of the flesinoxan nor between the
handled and the non-handled rats. The observed clearance
however is approximately twice as low as values reported
previously from our laboratory. In that particular study, rats
were only allowed to recover from surgery for 2 days,
whereas 8 days of recovery were allowed for rats in this
study, allowing full physical recovery (as judged by the
restoration of a circadian rhythm in body temperature and
locomotor activity). The large difference in pharmacoki-
netics between these two studies suggests that surgical
procedures and experimental setting can have a major
influence on the distribution and elimination of flesinoxan.
In order to quantify the pharmacodynamic properties of
flesinoxan, the hypothermic response and in the case of the
handled rats also the corticosterone response were chosen as
pharmacodynamic endpoints. The hypothermic response
behaves as an ideal bio-marker, as it is continuous, repro-
ducible, sensitive enough to discriminate between a full and
a partial agonist (Hadrava et al., 1995) and selective (Millan
et al., 1993; Cryan et al., 1999). We have recently developed
an integrated pharmacokinetic–pharmacodynamic model
which characterises 5-HT1A receptor-mediated hypothermia
in terms of potency and intrinsic activity (Zuideveld et al.,
2001). This model features a set-point control in combina-
tion with an indirect response model. As it is believed that
the 5-HT1A receptors play a role in maintaining the body’s
set-point temperature (Lin et al., 1983; Schwartz et al.,
1998; Zeisberger, 1998), and numerous reports suggest this
set-point is regulated through an interplay between the 5-
HT1A (hypothermia) and the 5-HT2A/C (hyperthermia)
receptor system (Gudelsky et al., 1986; Salmi and Ahlenius,
1998) this model is considered to reflect its physiology. The
set-point model allows 5-HT1A receptor agonists to attenu-
ate the set-point via a sigmoidal transducer function, allow-
ing for the estimation of potency and intrinsic activity. An
important feature of the model is that it allows character-
isation of the complex hypothermic time profiles that are
typically observed upon the administration of 5-HT1A
receptor agonists. For a full agonist, the model predicts that
the typical ‘plateau phase’ that is observed with a low dose
disappears with increasing dosages, as the oscillations
associated with the regulatory mechanism become ‘over-
damped’ (Zuideveld et al., 2001). This typical behaviour is
also observed for flesinoxan, which therefore behaves as a
full rather than a partial agonist. However, since slight
damping is observed and the absolute decrease in body
temperature is not as large as for example R-8-OH-DPAT’s
(4F0.3 jC; Zuideveld et al., 2001), it is estimated as a
partial agonist despite the fact that its effect is near maximal.
The parameters denoting the physiological part of the model
are highly similar to those estimated for R- and S-8-OH-
DPAT and buspirone in previous studies (Zuideveld et al.,
2001, 2002). Interestingly, the pharmacodynamic parame-
ters show that flesinoxan has a lower potency compared to,
for example, R-8-OH-DPAT (potency of 40 ng/ml (Zuide-
veld et al., 2001)) or buspirone (20 ng/ml (Zuideveld et al.,
unpublished observations)). In vitro affinities at the 5-HT1A
receptor are similar with KD values of flesinoxan of 8.8 nM
compared to 8.4 nM for R-8-OH-DPAT and 7.8 nM for
buspirone (Van Steen, 1996). Hence, there does not appear
to be a direct correlation between potencies found in vivo
and affinities found in vitro. This may in part be explained
by active transport processes at the blood–brain barrier.
Previous studies from our laboratory have shown that P-
glycoprotein efflux pumps may affect the equilibration
between blood and the brain (Van der Sandt et al., 2001),
and it is conceivable that estimating the potency based on
blood concentration results in an underestimation as com-
pared to the other 5-HT1A receptor agonists. However, other
possibilities, such as a different receptor reserve or different
receptor functionality for 8-OH-DPATand buspirone in vivo
for or on the 5-HT1A receptor should not be excluded.
Despite the fact that a significant difference in baseline
temperature was observed between the handled and the non-
handled group, no differences were observed in either the
physiological or pharmacodynamic parameters (see Table 3
for the mean, median, lower and upper values). This
indicated that after 1 week of handling, with the associated
surges in corticosterone, the net 5-HT1A receptor function
involved in the hypothermic effect had not changed. The
change in baseline temperature was not expected, although
higher baseline temperatures for rats which had been
handled have been reported previously (Michel and Cab-
anac, 1999). Whether the change in baseline temperature is
associated with a changed 5-HT1A receptor function is not
known. One could speculate however that 5-HT release in
the synaptic cleft has changed due to an altered receptor
function of for example the pre-synaptic 5-HT1A receptor.
The observed absolute corticosterone concentrations for
baseline levels of handled and non-handled rats are signifi-
cantly larger than values reported by several other studies
(Sibug et al., 1998, 2000; Fagin et al., 1983). It appears that
methodological factors play a role here. In the majority of
studies reported in the literature, corticosterone is measured
with either a commercially available or a ‘homemade’
radioimmunoassay (RIA). In the present investigation, how-
ever, a specific HPLC method has been used for the
quantification of the corticosterone concentrations. Cortico-
sterone concentrations reported by other authors using
HPLC assays are very similar to ours (Haughey and Jusko,
1988; Wong et al., 1994). Furthermore, ‘validation’ of our
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RIA kit did not yield a line of unity (results not shown).
Since the HPLC assay had been validated using a mass
spectrometer (Wong et al., 1994) and was sensitive enough
for this study, it was our method of choice.
In the modelling of the corticosterone effects, only data
from handled rats was considered, since in ‘non-handled’
rats, a profound baseline drift in corticosterone concentra-
tions is observed. Theoretically, it is possible to incorporate
such a change in the pharmacokinetic–pharmacodynamic
model, but this requires a mechanistic understanding of the
placebo response and the drug effect. In this respect, both
additive and more complex interaction models need to be
considered. At present, no specific information is available
regarding this interaction. At present, this makes it impos-
sible to come up with a realistic model for the simultaneous
analysis of the data from handled and ‘non-handled’ rats.
Interestingly, the rise in corticosterone level as observed
after administration of the 10 mg/kg dose of flesinoxan does
last significantly longer, than following 3 mg/kg, which is
consistent with the behaviour of an indirect physiological
response model (Dayneka et al., 1993). The increase in
corticosterone levels in the handled rats as a result of the 3
mg/kg administration of flesinoxan was described using the
indirect physiological response model. The value of the rate
constant associated with the elimination of corticosterone
from blood (kout) is considerably shorter than the elimina-
tion half-life of corticosterone as obtained on the basis of
analysis of the serum concentration versus time profile as
reported by other authors; 4.6 min (ln 2/kout) versus 25 min
(Sainio et al., 1988). In theory, these values should be
identical, and a comparison of these values could therefore
serve as a validation of the indirect physiological response
model (Van Schaick et al., 1997). With regards to the
reported value of the elimination half-life of 25 min, it is
important that this value was estimated after the adminis-
tration of a large dose of exogenous corticosterone, without
considering the endogenous corticosterone concentration
(Sainio et al., 1988). This may explain why the terminal
elimination half-life of corticosterone has been overesti-
mated in this previous investigation.
In the present investigation, the effects of flesinoxan on
both the lowering of body temperature and the cortico-
sterone response have been quantified on the basis of blood
concentrations. This makes it possible to compare the
pharmacodynamic parameter estimates for the two effects.
Interestingly the potency estimate for the rise in cortico-
sterone concentration is very similar to the potency found in
the hypothermic response. This suggests that the same tissue
or tissues with very similar a receptor densities and effi-
ciency of the receptor–effector coupling might mediate both
responses.
In the present study, the effect of flesinoxan on body
temperature and on corticosterone was characterised in an
integrated pharmacokinetic–pharmacodynamic analysis.
The hypothermic response was described using the recently
developed physiological set-point model. Despite the fact
that the baseline temperature of handled rats was signifi-
cantly increased, no differences were found in the hypo-
thermic response mediated by flesinoxan, nor in the
pharmacodynamic parameter estimates. This indicates that
‘handling’ has only minor effects on 5-HT1A receptor
function in vivo. The time course of increase in cortico-
sterone as observed after administration of flesinoxan was
successfully described using the indirect physiological
response model for the handled rats. The potencies found
between the hypothermic and the corticosterone effect
suggests that both effects are mediated by similar—if not
the same tissues.
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